Differential diagnosis of parkinsonism

Handbook of Parkinson's Disease, Third Edition

Volumn , Issue , 2003, Pages 43-69

  Sethi, Kapil D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055294564     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (144)

1. Quinn NP, Luthert P. Hanover M, Marsden CD. Pure akinesia due to Lewy body. Parkinson’s disease: a case with pathology. Move Disord 1989; 4:885-892.
2. Rajput AH. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1999; 53(6):1375.
3. Klein C, Pramstaller PP, Kis B, Page CC, Kann M, Leung J, Woodward H, Castellan CC, Scherer M, Vieregge P, Breakefield XO, Kramer PL, Ozelius LJ. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann Neurol 2000; 48(1):65-71.
4. Polymeropoulos MH. Autosomal dominant Parkinson’s disease and alpha-synuclein. Ann Neurol 1998; 44(3 suppl 1):S63-64.
5. Gasser T. Genetics of Parkinson’s disease. Ann Neurol 1998; 4(3 suppl 1):S53-71.
6. Paulson HL, Stern MB. Clinical manifestations of Parkinson’s disease. In: Watts RL, Koller WC, eds. Movement Disorders: Neurological Principles and Practice. New York: McGraw-Hill, 1997:183-199.
7. Findley LJ, Koller WC. Essential tremor. Clin Neuropharm 1989; 12:453-482.
8. Montgomery EB, Baker KB, Koller WC, Lyons K. Motor initiation and execution in essential tremor and Parkinson’s disease. Mov Disord 2000; 3:511-515.
9. Pahwa R, Koller WC. Is there a relationship between Parkinson’s disease and essential tremor? Clin Neuropharm 1993; 16:30-35.
10. Hardie RJ, Lees AJ. Neuroleptic induced Parkinson’s syndrome. Clinical features and results of treatment with levodopa. Neurology 1987; 37:850-854.
11. Stephen PJ, Williams J. Drug-induced parkinsonism in the elderly. Lancet1987; 2:1082.
12. Mutch WJ, Dingwall-Fordyce I, Downie AW, et al. Parkinson’s disease in a Scottish city. Br Med J 1986; 292:534-536.
13. Sethi KD, Zamrini EY. Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsych Clin Neurosci 1990; 2:64-66.
14. Giladi N, Kao R, Fahn S. Freezing phenomenon in patients with parkinsonian syndromes. Mov Disord 1997; 12(3):302-305.
15. Klawans HL, Bergan D, Bruyn GW. Prolonged drug induced parkinsonism. Confin Neurol 1973; 35:368-377.
16. LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, Srivatsva DK, Oakes D. Markers of dopamine metabolism in Parkinson’s disease. Neurology 1992; 42:2111-2117.
17. 18flurodopa PET study. Neurology 1993; 43:552-556.
18. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. Arch Neurol 1964; 10:333-359.
19. Steele JC. Progressive supranuclear palsy. Brain 1972; 95:693-704.
20. Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988; 38:1031-1034.
21. Nuwer MR. Progressive supranuclear palsy despite normal eye movements. Arch Neurol 1981; 38:784.
22. Troost B, Daroff R. The ocular motor defects in progressive supranuclear palsy. Ann Neurol 1977; 2:397-403.
23. Vidailhet M, Rivaud S, Gouider-Khouja N, et al. Eye movements in parkinsonian syndromes. Ann Neurol 1994; 35:420-426.
24. Barclay CL, Lang AE. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997; 62(4):352-356.
25. Masucci EF, Kurtzke JF. Tremor in progressive supranuclear palsy. Acta Neurol Scand 1989; 80:296-300.
26. Schonfeld SM, Golbe LI, Sage JI, Safer JN, Duvoisin RC. Computed tomographic findings in progressive supranuclear palsy: correlation with clinical grade. Mov Disord 1987; 2:263-278.
27. Savoiardo M, Girotti F, Strada L, Cieri E. Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. J Neural Transm Suppl 1994; 42:93-110.
28. Yagishita A, Oda M. Progressive supranuclear palsy: MRI and pathological findings. Neuroradiology 1996; 38(suppl 1):S60-66.
29. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28:547-555.
30. Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measures with C-raclopride and positron emission tomography. Ann Neurol 1992; 31:184-192.
31. Fearnley JM, Revesz T, Brooks DJ, Frackowiak RS, Lees AJ. Diffuse Lewy body disease presenting with a supranuclear gaze palsy. J Neurol Neurosurg Psychiatry 1991; 54:159-161.
32. De Bruin VM, Lees AJ, Daniel SE. Diffuse Lewy body disease presenting with supranuclear gaze palsy, parkinsonism, and dementia: a case report. Mov Disord 1992; 7:355-358.
33. Foster NL, Gilman S, Berent S, et al. Progressive subcortical gliosis and progressive supranuclear palsy can have similiar clinical and PET abnormalities. J Neurol Neurosurg Psychiatry 1992; 55:707-713.
34. Lees AJ, Gibb W, Barnard RO. A case of progressive subcortical gliosis presenting clinically as Steele-Richardson Olszewski syndrome. J Neurol Neurosurg Psychiatry 1988; 51:1224-1227.
35. Dubinsky RM, Jankovic J. Progressive supranuclear palsy and a multi-infarct state. Neurology 1987; 37:570-576.
36. Winikates J, Jankovic J. Vascular progressive supranuclear palsy. J Neural Transm Suppl 1994; 42:189-201.
37. Fink JK, Filling- Katz MR, Sokol J et al. Clinical spectrum of Niemann-Pick disease type C Neurology 1989; 39:1040-1049.
38. Quinn N. Multiple system atrophy. In: Marsden C, Fahn S, eds. Movement Disorders. Newton, MA: Butterworth-Heinemann, 1994:262-281.
39. Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989; 112:1171-1192.
40. Litvan I, Agid Y, Jankovic J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996; 46:922-930.
41. Litvan I, Agid Y, Calne D, Campbell G et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) report of the NINDS-SPSP international workshop. Neurology1996; 47:1-9.
42. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psych1969; 32:28-34.
43. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy; an analysis of 100 cases. Brain 1994; 117:835-845.
44. Van Eecken H, Adams RD, and Van Bogaert, L. Striopallidal-nigral degeneration. J Neuropathol Exp Neurol 1960; 19:159-166.
45. Adams RA, Van Bogaert L, Van der Eecken H. Striato-nigral degeneration. J Neuropathol Exp Neurol 1964; 23:584-608.
46. Wenning GK, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord1997; 12:133-147.
47. Rajput AH, Kazi KH, Rozdilsky B. Striatonigral degeneration, response to levodopa therapy. J Neurol Sci 1972; 16:331-341.
48. Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psych 1992; 55:1009-1013.
49. Lang AE, Birnbaum A, Blair RDG, Kierans C. Levodopa related response fluctuations in presumed olivopontocerebellar atrophy. Mov Disord 1986; 1:93-102.
50. Quinn NP. Unilateral facial dystonia in multiple system atrophy. Mov Disord1992; 7(suppl):79.
51. Shy GM, Drager GA. A neurologic syndrome associated with orthostatic hypotension. Arch Neurol 1960; 2:511-527.
52. Wu YR, Chen CM, Ro LS, Chen ST, Tang LM. Vocal cord paralysis as an initial sign of multiple system atrophy in the central nervous system. J Formosan Med Assoc 1996; 95(10):804-806.
53. Bonnet AM, Pichon J, Vidailhet M, Gouider-Khouja N, Robain G, Perrigot M, Agid Y. Urinary disturbances in striatonigral degeneration and Parkinson’s disease: clinical and urodynamic aspects. Mov Disord 1997; 12(4):509-513.
54. Kirby R, Fowler C, Gosling J, Bannister R. Urethro-vesical dysfunction in progressive autonomic failure with multiple system atrophy. J Neurol Neurosurg Psychiatry 1986; 49:554-562.
55. Valldeoriola F, Valls-Sole E, Tolosa S, Marti MJ. Striated anal sphincter denervation in patients with progressive supranuclear palsy. Mov Disord1995; 10(5):550-555.
56. Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54:697-702.
57. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 1996; 47:1113-1124.
58. Mega MS, Masterman DL, Benson DF, Vinters HV, Tomiyasu U, Craig AH, Foti DJ, Kaufer D, Scharre DW, Fairbanks L, Cummings JL. Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. Neurology 1996; 47(6):1403-1409.
59. Ala TA, Yang KH, Sung JH, Frey WH. Hallucinations and signs of Parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer’s disease at presentation: a clinicopatho-logical study. J Neurol Neurosurg Psychiatry 1997; 62(1):16-21.
60. Rebeiz JJ, Kolodny EH, Richardson EP. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968; 18:220-223.
61. Riley De, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology 1990; 40:1203-1212.
62. Rinne Jo, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration: a clinical study of 36 cases. Brain 1994; 117:1183-1196.
63. Chen R, Ashby P, Lang AE. Stimulus-sensitive myoclonus in akinetic-rigid syndromes. Brain 1992; 115:1875-1888.
64. Litvan I, Agid Y, Gostz C, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathological study. Neurology 1997; 48:119-125.
65. Lang AE, Bergeron C, Pollanen MS, Ashby P. Parietal Pick’s disease mimicking cortical-basal ganglionic degeneration. Neurology 1994; 44:1436-1440.
66. Katai S, Maruyama T, Nakamura A, Tokuda T, Shindo M, Yanagisawa N. A case of corticobasal degeneration presenting with primary progressive aphasia. Rinsho Shinkeigaku Clin Neurol 1997; 37(3):249-252.
67. Grisoli M, Fetoni V, Savoiardo M, Girotti F, Bruzzone MG. MRI in corticobasal degeneration. Eur J Neurol 1995; 2:547-552.
68. Nagasawa H, Tanji H, Nomura H, Saito H, Itoyama Y, Kimura I, Tuji S, Fujiwara T, Iwata R, Itoh M, Ido T. PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration. J Neurol Sci 1996; 139(2):210-217.
69. Neary D, Snowden J, Gustafsson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51:1546-1554.
70. Gustaffson L. The clinical picture of frontal lobe degeneration of nonAlzheimer type. Dementia 1993; 4:143-148.
71. Pasqueir F, Lebert F, Lavenu I, Guillaume B. The clinical picture of frontotemporal dementia: diagnosis and follow-up. Geriatr Cogn Disord1999; 109(suppl 1):10-14.
72. Rinne JO, Laine M, Kaasinen V, et al. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology 2002; 58:1489-1493.
73. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary intravenous injection of meperidine analogues. Psychiatry Res 1979; 1:249-254.
74. Langston JW, Ballard P, Tetrud J, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219:979-980.
75. Tetrud JW, Langston JW, Garbe PL, Ruttenber JA. Early parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurology 1989; 39:1482-1487.
76. Langston JW, Ballard PA. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson’s disease. Can J Neurol Sci 1984; 11:160-165.
77. Langston JW. MPTP-induced parkinsonism: How good a model is it? In: Fahn S, Marsden CD, Teychenne P, Jenner P, eds. Recent advances in Parkinson’s disease. New York: Raven Press, 1986:119-126.
78. Huang CC, Chu NS, Song C, Wang JD. Chronic manganese intoxication. Arch Neurol 1989; 46:1104-1112.
79. Barbeau A. Manganese and extrapyramidal disorders. Neurotoxicology 1984; 5:113-136.
80. Racette BA, McGee- Minnich L, Moerlein SM, Mink JW, Videen TO, Perlmutter JS. Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology 2001; 56(1):8-13.
81. Min SK. A brain syndrome associated with delayed neuro-psychiatric sequelae following acute carbon monoxide intoxication. Acta Psychiatr Scand1986; 73:80-86.
82. Lee MS, Marsden CD. Neurological sequelae following carbon monoxide poisoning: Clinical course and outcome according to the clinical types and brain computed tomography scan findings. Mov Disord 1994; 9:550-558.
83. Miura T, Mitomo M, Kawai R, Harada, CT of the brain in acute carbon monoxide intoxication. Characteristic features and prognosis. AJNR 1985; 6:739-742.
84. Kobayashi K, Isaki K, Fukutani Y, et al. CT findings of the interval form of carbon monoxide poisoning compared with neuropathological findings. Eur Neurol 1984; 23:34-43.
85. Vieregge P, Klostermann W, Blumm RG, Borgis KJ. Carbon monoxide poisoning: clinical, neurophysiological and brain imaging observations in acute phase and follow up. J Neurol 1989; 239:478-481.
86. Peters HA, Levine RL, Matthews CG, Chapman LJ. Extrapyramidal and other neurological manifestations associated with carbon disulfide fumigant exposure. Arch Neurol 1988; 45:537-540.
87. Uitti RJ, Rajput AH, Aashenhurst EM, Rozkilsky B. Cyanide-induced parkinsonism: a clinicalopathologic report. Neurology 1985; 35:921-925.
88. Rosenberg NL, Myers JA, Wayne WR. Cyanide-induced parkinsonism: clinical, MRI, and 6-fluorodopa PET studies. Neurology 1989; 39:142-144.
89. Guggenheim MA, Couch JR, Weinberg W. Motor dysfunction as a permanent complication of methanol ingestion. Arch Neurol 1971; 24:550-554.
90. Mclean DR, Jacobs H, Mielki BW. Methanol poisoning a clinical and pathological study. Ann Neurol 1980; 8:161-167.
91. Factor SA, Sanchez-Ramos J, Weiner WJ. Trauma as an etiology of parkinsonism: a historical review of the concept. Mov Disord 1988; 3:30-36.
92. Factor SA. Posttraumatic parkinsonism. In: Stern MB, Koller WC, eds. Parkinsonian Syndromes. New York: Marcel Dekker, 1993:95-110.
93. Critchley M. Medical aspects of boxing, particularly from a neurological standpoint. Br Med J 1957; 1:357-362.
94. Martland HS. Punch drink. J Am Med Assoc 1928; 91:1103-1107.
95. Critchley M. Arteriosclerotic parkinsonism. Brain 1929; 52:23-83.
96. Fitzgerald PM, Jankoic J. Lower body parkinsonism: evidence for a vascular etiology. Mov Disord 1989; 4:249-260.
97. Parkes JD, Marsden CD, Rees JE, et al. Parkinson’s disease: Cerebral arteriosclerosis and senile dementia. Q J Med 1974; 43:49-61.
98. Thompson PD, Marsden CD. Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger’s disease. Mov Disord 1987; 2:1-8.
99. Mark MH, Sage JI, Walters AS, et al. Binswanger’s disease presenting as L-dopa-responsive parkinsonism: clinicopathologic study of three cases. Mov Disord 1995; 10:450-454.
100. Hurtig HI. Vascular parkinsonism. In: Stern MB, Koller WC, eds. Parkinsonian Syndromes. New York: Marcel Dekker, 1993:81-93.
101. Krauss JK, Regel JP, Droste DW, Orszag M, Boremanns JJ, Vach W. Movement disorders in adult hydrocephalus. Mov Disord 1997; 12:53-60.
102. Hakim S, Adams RD. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid hydrodynamics. J Neurol Sci1965; 2:307-327.
103. Jacobs L, Conti D, Kinkel WR, Manning EEG. A Normal pressure hydrocephalus: relationship of clinical and radiographic findings to improvement following shunt surgery. JAMA 1976; 235(5):510-512.
104. Ahlberg J, Norlen L, Blomstrand C, Wikkelso C. Outcome of shunt operation on urinary incontinence in normal pressure hydrocephalus predicted by lumbar puncture. J Neurol Neurosurg Psychiatry 1988; 51:105-108.
105. Waters CH. Structural lesions and parkinsonism. In: Stern MB, Koller WC, eds. Parkinsonian syndromes. New York: Marcel Dekker, 1993:137-144.
106. Blocq, Marinesco G. Sur un cas tremblement parkinsonien hemiplegique symptomatique dune tumeur de pedoncule cerebral. Cr Soc Biol 1893; 45:105-111.
107. Samiy E. Chronic subdural hematoma presenting a parkinsonian syndrome. J Neurosurg 1963; 20:903.
108. Adler CH, Stern MB, Brooks ML. Parkinsonism secondary to bilateral striatal fungal abscesses. Mov Disord 1989; 4:333-337.
109. Murphy MJ. Clinical correlations of CT scan-detected calcification of the basal ganglia. Ann Neurol 1979; 6:507-511.
110. Lang AE, Koller WC, Fahn S. Psychogenic parkinsonism. Arch Neurol 1995; 52:802-810.
111. Quinn N, Critchley P, Marsden CD. Young onset Parkinson’s disease. Mov Disord 1987; 2:73-91.
112. Gershanik OS. Early-onset parkinsonism. In: Jankovic J, Tolosa E, eds. Parkinson’s Disease and Movement Disorders. Baltimore: Williams &Wilkins, 1993:235-252.
113. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1991; 41:174-181.
114. Snow BJ, Nygaard TG, Takahashi H, Calne DB. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism. Ann Neurol 1993; 34:733-738.
115. Dobyns WB, Goldstein NNP, Gordon H. Clinical spectrum of Wilson’s disease (hepatolenticular degeneration). Mayo Clin Proc 1979; 54:35-42.
116. Walshe JM, Yealland M. Wilson’s disease: the problem of delayed diagnosis. J Neurol Neurosurg Psychiatry 1992; 55:692-696.
117. Topaloglu H, Gucuyener K, Orkun C, Renda Y. Tremor of tongue and dysarthria as the sole manifestation of Wilson’s disease. Clin Neurol Neurosurg 1990; 92:295-296.
118. Cheinberg IH, Sternlieb I, Richman J. Psychiatric manifestations of Wilson’s disease. Birth defects. Orig Art Ser 1968; 4:85-86.
119. Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912; 34:295-509.
120. Weilleit J, Kiechl SG. Wilson’s disease with neurological impairment but no Kayser-Fleischer rings. Lancet 1991; 337:1426.
121. Demirkiran M, Jankovic J, Lewis RA, Cox DW. Neurologic presentation of Wilson disease without Kayser-Fleischer rings. Neurology 1996; 46(4):1040-1043.
122. Nelson RF, Guzman DA, Grahovaac Z, Howse DCN. Computerized tomography in Wilson’s disease. Neurology 1979; 29:866-868.
123. Dettori P, Rochelle MB, Demalia L, et al. Computerized cranial tomography in presymptomatic and hepatic form of Wilson’s disease. Eur Neurol 1984; 23:56-63.
124. King AD, Walshe JM, Kendall BE, Chinn RJ, Paley MN, Wilkinson ID, Halligan S, Hall-Craggs MA. Cranial MR imaging in Wilson’s disease. Am J Roentgenol 1996; 167(6):1579-1584.
125. Steindl P, Ferenci P, Dienes HP, Grimm G, Pabinger I, Madl C, MaierDobersberger T, Herneth A, Dragosics B, Meryn S, Knoflach P, Granditsch G, Gangl A. Wilson’s disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997; 113(1):212-218.
126. Saatci I, Topcu M, Baltaoglu FF, Kose G, Yalaz K, Renda Y, Besim A. Cranial MR findings in Wilson’s disease. Acta Radiol 1997; 38(2):250-258.
127. Snow BJ, Bhatt M, Martin WR, et al. The nigrostriatal dopaminergic pathway in Wilson’s disease studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991; 54:12-17.
128. Scheinberg IH, Sternlieb I. Wilson’s disease: Major Problems in Internal Medicine. Vol. 23. Philadelphia: W. B. Saunders, 1984.
129. Brewer GJ, Yuzbasiyan-Gurkan V. Wilson’s disease. Medicine 1992; 71:139-164.
130. Sethi KD, Adams RJ, Loring DW, EL Gammal T. Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol1988; 24:692-694.
131. Adams P, Falek A, Arnold J. Huntington’s disease in Georgia: age at onset. Am J Hum Genet 1988; 43:695-704.
132. Klawans HL. Hemiparkinsonism as a late complication of hemiatrophy: a new syndrome. Neurology 1981; 31:625-628.
133. Buchman AS, Christopher GG, Goetz MD, Klawans HI. Hemiparkinsonism with hemiatrophy. Neurology 1988; 38:527-530.
134. Przedborski S, Giladi N, Takikawa S, et al. Metabolic topography of the hemiparkinsonism-hemiatrophy syndrome. Neurology 1994; 44:1622-1628.
135. Waters CH, Faust PL, Powers J, et al. Neuropathology of lubag (X-linked dystonia-parkinsonism). Mov Disord 1993; 8:387-390.
136. Spitz MC, Jankovic J, Killian JM. Familial tic disorder, parkinsonism, motor neuron disease and acanthocytosis: a new syndrome. Neurology 1985; 35:366-370.
137. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology 1992; 42:1142-1146.
138. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56:33-39.
139. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988; 51:745-752.
140. Ward C, Gibb W. Research diagnostic criteria for Parkinson’s disease. In: Streifler M, Korczyn A, Melamed E, Youdim M, eds. Advances in Neurology: Parkinson’s Disease: Anatomy, Pathology, and Therapy. New York: Raven Press, 1990.
141. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism prospective study. Can J Neurol Sci 1991; 18:275-278.
142. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181-184.
143. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 2001; 57:1497-1499.
144. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125:861-870.